228 related articles for article (PubMed ID: 35964806)
1. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
[TBL] [Abstract][Full Text] [Related]
2. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
Okumura H; Fukushima A; Taieb V; Shoji S; English M
J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
[TBL] [Abstract][Full Text] [Related]
3. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
Tashiro S; Taguchi K; Enoki Y; Matsumoto K
Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
Nelson RL; Suda KJ; Evans CT
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
[TBL] [Abstract][Full Text] [Related]
5. The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
Stabholz Y; Paul M
Clin Microbiol Infect; 2024 Jan; 30(1):51-58. PubMed ID: 37690610
[TBL] [Abstract][Full Text] [Related]
6. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
[TBL] [Abstract][Full Text] [Related]
7. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials.
Igarashi Y; Tashiro S; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
J Infect Chemother; 2018 Nov; 24(11):907-914. PubMed ID: 30170735
[TBL] [Abstract][Full Text] [Related]
8. Optimal therapeutic recommendation for Clostridioides difficile infection in pediatric and adolescent populations: a systematic review and meta-analysis.
Tashiro S; Mihara T; Okawa R; Tanaka Y; Samura M; Enoki Y; Taguchi K; Matsumoto K; Yamagishi Y
Eur J Pediatr; 2023 Jun; 182(6):2673-2681. PubMed ID: 37000258
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
10. Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.
Kravets AM; Hanneke R; Nelson RL
Tech Coloproctol; 2023 Dec; 28(1):20. PubMed ID: 38112980
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
[TBL] [Abstract][Full Text] [Related]
12. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Okumura H; Ueyama M; Shoji S; English M
J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
[TBL] [Abstract][Full Text] [Related]
14. Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating
Mori N; Hirai J; Ohashi W; Asai N; Shibata Y; Mikamo H
Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627743
[No Abstract] [Full Text] [Related]
15. Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.
Muhammad A; Simcha W; Rawish F; Sabih R; Albert E; Ali N
Curr Clin Pharmacol; 2020; 15(1):4-10. PubMed ID: 31376824
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity.
Di X; Bai N; Zhang X; Liu B; Ni W; Wang J; Wang K; Liang B; Liu Y; Wang R
Braz J Infect Dis; 2015; 19(4):339-49. PubMed ID: 26001980
[TBL] [Abstract][Full Text] [Related]
17. A prospective, observational study of fidaxomicin use for
Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
[TBL] [Abstract][Full Text] [Related]
18. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
Collins DA; Riley TV
Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
[TBL] [Abstract][Full Text] [Related]
19. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
20. Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis.
Dai J; Gong J; Guo R
Eur J Clin Pharmacol; 2022 Nov; 78(11):1727-1737. PubMed ID: 36057672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
